Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA
First patients recruited for bladder cancer recurrence monitoring study
News provided by
Share this article
SUNDERLAND, England, July 27, 2021 /PRNewswire/
ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe.
ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for
More Data Support Active Surveillance for Small Renal Masses medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: There Is No Role for Radical Cystectomy in cT0 After Neoadjuvant Chemotherapy
(UroToday.com) At the European Association of Urology 2021 Meeting’s controversies in Onco-Urology session, Dr. Alexandra Masson-Lecomte discussed that there is no role for radical cystectomy in cT0 disease after neoadjuvant chemotherapy.
Dr. Masson-Lecomte noted that up to 5-15% of patients will have T0 disease after TURBT alone, which increases to 25-38% after MVAC after neoadjuvant chemotherapy based an analysis of the Nordic I, Nordic II, SWOG, and MRC trials.
1 More recently, presented at the ASCO GU 2020 meeting, preliminary results from the randomized phase III GETUG/AFU VESPER trial for treatment of muscle-invasive urothelial bladder cancer showed that with dose-dense MVAC, pT0 rates of 42% are attainable.
EAU 2021: Radiotherapy After Radical Prostatectomy in the PSMA-PET Era
(UroToday.com) At the controversies in Onco-Urology session of the European Association of Urology 2021 annual meeting, Dr. Alberto Bossi discussed radiotherapy after radical prostatectomy in the PSMA-PET era. Adjuvant radiotherapy is defined as immediate postoperative radiation in the case of extraprostatic extension, positive margins, seminal vesicle infiltration, high Gleason score, or pN+ disease. Salvage radiotherapy is defined as a wait-and-see policy in that radiation is only given in the case of a rising postoperative PSA.
The ARTISTIC meta-analysis was published in 2020, combining data from RADICALS, GETUG-AFU 17, and RAVES showing no difference in PSA-driven event-free survival with a hazard ratio of 1.12 (95% CI 0.88-1.42), and a potential absolute difference of 1% at 5-years in favor of early salvage radiotherapy
EAU 2021: Evolving Landscape of First-Line Systemic Treatment in Metastatic Renal Cell Carcinoma urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.